menu
    • menu

    Company profile for Natera

    NEW Drugs in Dev: 4
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Natera is looking for high performers who enjoy collaborating with others to solve complex problems and create meaningful solutions. When you join Natera, you’ll work hard and grow quickly. Working alongside the elite of the industry, you’ll be stretched and challenged, and take pride in being part of a company that is changing the landscape of genetic disease management.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NateraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    201 Industrial Rd San Carlos, CA 94070
    Telephone
    Telephone
    650.249.9090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Natera Announces Commercial Launch of Zenith Genomics
    Natera Announces Commercial Launch of Zenith Genomics

    12 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260312908723/en/Natera-Announces-Commercial-Launch-of-Zenith-Genomics-for-Rare-Disease-Diagnosis

    BUSSINESSWIRE
    12 Mar 2026
    Share Share
    Signatera MRD Data at ASCO GU Support Use Across GU Cancers
    Signatera MRD Data at ASCO GU Support Use Across GU Cancers

    27 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260227178662/en/Signatera-MRD-Data-at-ASCO-GU-Highlights-Potential-Utility-Across-GU-Cancers-Including-for-Bladder-Preservation

    BUSINESSWIRE
    27 Feb 2026
    Share Share
    Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment
    Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment

    24 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224679603/en/Successful-Readout-of-Prospective-Phase-2-SINERGY-Trial-Supports-SignateraTM-MRD-Guided-Treatment-in-Head-and-Neck-Cancer

    BUSINESSWIRE
    24 Feb 2026
    Share Share
    Natera To Release Q4 And Full Year Results On Feb. 26, 2026
    Natera To Release Q4 And Full Year Results On Feb. 26, 2026

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260217867631/en/Natera-to-Report-its-Fourth-Quarter-and-Full-Year-Results-on-February-26-2026

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    Natera Initiates EDEN Study For Early Preeclampsia Risk
    Natera Initiates EDEN Study For Early Preeclampsia Risk

    06 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260206350770/en/Natera-Launches-EDEN-Study-on-Early-Risk-Assessment-for-Preeclampsia-and-Adverse-Pregnancy-Outcomes

    BUSINESSWIRE
    06 Feb 2026
    Share Share
    Natera Submits Signatera CDx PMA to FDA
    Natera Submits Signatera CDx PMA to FDA

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260129560151/en/Natera-Submits-Signatera-CDx-PMA-to-FDA

    BUSINESSWIRE
    02 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search